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Novel technologies for early diagnosis of Alzheimer’s disease (AD) will impact the way society views and deals with AD and
ageing. However, such “sociocultural” impacts are hardly acknowledged in standard approaches of technology assessment. In
this paper, we outline three steps to assess such broader impacts. First, conceptual analysis of the ideas underlying technological
developments shows how these technologies redraw the boundary between Alzheimer’s disease and normal ageing and between
biological and social approaches of ageing. Second, imaginative scenarios are designed depicting diﬀerent possible futures of AD
diagnosis and societal ways to deal with ageing and the aged. Third, such scenarios enable deliberation on the sociocultural impact
of AD diagnostic technologies among a broad set of stakeholders. An early, broad, and democratic assessment of innovations in
diagnostics of AD is a valuable addition to established forms of technology assessment.
1.Introduction
The early detection of Alzheimer’s disease is a widely shared
goal in current biomedical research. At many labs and in
manyhospitals around the world, scientists areworking hard
to develop knowledge and technologies to enable such early
detection. Most attempts are focused on the identiﬁcation
of biomarkers that might indicate early stage Alzheimer’s
or even predict the disease. Recent recommendations and
proposals to adapt the deﬁnition of and the guidelines for
diagnosing Alzheimer’s disease reﬂect these endeavors. The
new guidelines by the American National Institute on Aging
and the Alzheimer’s Association conceive AD as a three-
staged disease process, including a preclinical stage, a stage of
mildcognitiveimpairment,andtheﬁnalstageofAlzheimer’s
dementia. The authors of these guidelines suggest that
biomarkers can play a role in delineating the preclinical as
well as the mild cognitive impairment stage and might be
used to increase the certainty that AD pathophysiology is the
basis of the clinical syndrome [1, 2]. In the proposals for the
DSMV,Alzheimer’sDiseaseisincludedasasubtypeofmajor
as well as minor neurocognitive disorders. In the case of
minor neurocognitive disorders, the category most relevant
to early detection, the proposal requires not only evidence
of memory complaints, but also “supporting evidence for
the Alzheimer etiology (e.g., a positive test for a known
mutation in an Alzheimer’s disease associated gene) or
with evolving research, documentation based on biomarkers
or imaging” [3]. In both the NIA/AA guidelines and the
DMS V proposals, then, molecular biomarkers are expected
to play an important role in delineating and diagnosing
stages preceding full-blown AD, even though their precise
contribution is still unclear.
This does not mean, however, that early detection of
Alzheimer’s Disease is uncontroversial. Researchers working
on such early detection may be confronted with questions
about, for example, the value of early detection when a cure
for Alzheimer’s is still lacking, about the potential medical-
ization of the ageing process, about the right of potential
Alzheimer patients/families to codecide on a technology that
might have a great impact on their lives, and about the
distribution of liabilities. These are diﬃcult questions to deal2 International Journal of Alzheimer’s Disease
with, and scientists may not be in the best position to answer
them. From a societal perspective, however, it is important
that such considerations are taken into account before early
detection for Alzheimer’s disease is introduced at a wide
scale.
Health technology assessment (or medical technology
assessment) is often used by policy makers to judge the
desirability of novel technologies before they are introduced.
However,mostformsofHTAarelimitedinscope.Theyfocus
on the clinical eﬃcacy of the novel diagnostic or therapeutic
tool, its potential risks or side eﬀects, and its eﬃciency. The
fact that those technologies might also have an impact on the
organization of medical practice and on society and culture
at large, is neglected. Such sociocultural impacts are, of
course,diﬃculttoforesee,letalonetoquantify.Thisdoesnot
make them less relevant, however. If we want to include such
broader impacts, a diﬀerent type of assessment is needed in
addition to the quantitative tools of HTA.
In this paper, we describe how sociocultural impacts
(in particular impacts on views on and practices of ageing)
could be included in the assessment of emerging diagnostic
technologies for Alzheimer’s disease. After explaining the
practical and theoretical background of the research from
which this paper resulted, we will outline the three steps
of our approach. First, a conceptual analysis of the ideas
underlying technological developments can show how a
new type of diagnosis might redraw the boundary between
Alzheimer’s disease and normal ageing. Second, we investi-
gate how possible futures can be represented to stakeholders.
A promising route is to produce imaginative sociotechnical
scenariosdepictingdiﬀerentpossiblefuturewaystodealwith
AD, ageing, and the aged. Third, we review the possibilities
for deliberation on the potential sociocultural impacts.
Scenarios like the ones outlined here can be presented to
a broad set of stakeholders (including patients, families,
medical professionals, medical industry, policy, and insur-
ance companies), which allows an interactive assessment of
sociocultural impacts. We conclude that the potential of
currentinnovationsindiagnosticsofADmeritsademocratic
assessment, including an early and broad assessment of
sociocultural impacts.
2. PracticalandTheoretical Background
The work described here originated in the context of a
multidisciplinary research project, in which philosophers,
ethicists, and social scientists cooperate with a Dutch
biomedical research consortium developing molecular tools
for early detection of Alzheimer’s. The biomedical research
project is called the “Leiden Alzheimer Research Nederland”
or LeARN-project. Partners in the consortium are Leiden
University Medical Centre, VU University Medical Centre,
University Medical Centre St. Radboud, Maastricht Univer-
sity Medical Centre, Philips Electronics, Schering Plough
(part of MSD), BAC, Cyclotron and Virtual Proteins. The
LeARN-project is funded by the Centre for Translational
Molecular Medicine. (For more information on the CTMM
and the LeARN-project, http://www.ctmm.nl/.) The multi-
disciplinaryprojectfromwhichthispaperoriginatesusesthe
LeARN-project as a case study, but is independently funded
by the Dutch Organization for Scientiﬁc Research (NWO).
The LeARN consortium aims to develop tools for early
diagnosis of AD. Three types of medical technology are used
to achieve this goal: PET scans, MRI scans, and CSF analysis.
The biomedical project investigates which (combination of)
molecular biomarkers are able to detect AD in a suﬃciently
reliable way. The aim of our multidisciplinary project is
to contribute to responsible innovation by anticipating the
potential social and ethical aspects of early (molecular)
diagnosis of AD as developed within the LeARN project. Our
reﬂections on the potential impact of this type of emerging
technologies, however, are relevant to any attempt to ﬁnd
molecular biomarkers for early diagnosis of AD.
One of the starting points of our project is the obser-
vation that new biomedical technologies may have a broad
set of impacts on medical practice, society, and culture, but
that society hardly takes these into account when assessing
the desirability of a novel technology. This is unfortunate,
both from an ethical as well as a practical point of view.
In an ethical sense, responsible innovation means that the
innovation at hand should be acceptable to all those for
whom something is at stake in the innovation process. And
this, in turn, presupposes that these stakeholders have the
opportunity to reﬂect on all types of considerations on the
desirability of an innovation [4, 5]. A more democratic
innovation process should address this wider set of consider-
ations.Onapracticalnote,anticipatingthepotentialbroader
impactofatechnologyhelpstopreventunpleasantsurprises,
or even a backlash, later on [6–8]. As, for example, scientists
working on the genetic modiﬁcation of crops learnt to their
dismay, not all innovation that seems useful to science is
embraced by a lay public. Many medical innovations as
well never make it to daily use in health care because they
do not ﬁt the needs and values of their targeted users.
Anticipating the impact of emerging technologies in society
may contribute to more robust and useful technologies.
This is, however, hard to realize. After all, emerging
technologies do not exist yet and are characterized by many
uncertainties. It is not clear yet what they will look like,
how they will perform, and how they will be used, and this
m a k e si td i ﬃcult to determine how desirable they might be
for future users. It may even be diﬃcult to identify who
these users will be. In the case of early detection for AD,
for example, it is far from clear which (set of) molecular
biomarkers will prove to be suﬃciently reliable (if any), how
useful they will be for prognosis, who would use this type
of diagnostics, and in what way. This might be an argument
to ﬁrst wait and see and not to speculate on things to come
before the technology has evolved to the stage of a prototype
or can be experimented with. However, in social studies
of science and technologies, it is well known that at such
a later stage it is much more diﬃcult to steer technology
development in a diﬀerent direction. So, we may be caught
in what Collingridge [9] called the “dilemma of control”:
at an early stage of technology development, it is diﬃcult
to foresee what the technology will be like and what it will
do, but at a later stage it is too late to eﬀectively steer the
development.International Journal of Alzheimer’s Disease 3
One approach developed in science and technology stud-
ies to circumvent this problem is “constructive technology
assessment” (CTA) [6, 10]. Starting from the assumption
that early anticipation of future developments is necessary to
enable any attempt at socially orienting technology develop-
ment, this approach aims to engage stakeholders early on. In
such engagement activities, ideals and expectations guiding
the work of technology developers can be scrutinized and
opened up for broader deliberation, ultimately leading to
a broadening of the criteria used to design a socially and
ethically desirable technology.
One of the tools used in engagement activities are “so-
ciotechnical scenarios” that tease out the diﬀerent ways in
which technology, society, and culture (including morality)
might interact with each other [11, 12]. The use of scenarios
has its origin in business strategy and later on also in policy
studies [13]. In particular, the famous Shell group developed
a methodology to produce and use scenarios [14, 15].
Scenarios are neither predictive, nor completely ﬁctitious. In
general, they are used to test whether strategies are robust
underunexpectedfuturecircumstances.Thepluralcharacter
of scenarios enables business leaders or policy makers to
prepare for the future, whatever in the end will be realized.
Since they are grounded in both historical analysis and
an exploration of how diﬀerent stakeholders respond to
the developments at hand, the narratives can be charac-
t e r i z e da sp r o d u c t so f“ c o n t r o l l e ds p e c u l a t i o n ”[ 16]. Using
such scenarios in focus groups or interactive workshops
with stakeholders enables sensible deliberation on emerging
technologies, while at the same time acknowledging the
uncertainties involved [10].
The project described here also attempts to create
space for stakeholder engagement early in the process of
technology development and to provide input for such
engagement in the form of controlled speculation on the
future. More than other CTA projects, however, it builds
on a conceptual analysis of the mutual interaction between
concepts of disease (i.e., AD) and ageing on the one
hand, and technology development on the other. As argued
by Boenink [17], the analysis of emerging shifts in the
concepts of disease and health helps to anticipate ethical
issues related to emerging biomedical technologies. Whereas
the particular direction and performance of an emerging
technology may still be uncertain, the underlying framings
of disease and health, or normality and abnormality, are
often visible at an early stage already. Such conceptual shifts
help us to anticipate subsequent shifts in the organization
of health care and nonmedical practices, thus opening them
up for ethical and social debate. This is particularly true
for technologies related to Alzheimer ’s disease, since the
history of Alzheimer’s disease shows how novel diagnostic
and therapeutic technologies for AD framed the disease and,
by implication, also views of ageing in new and unexpected
ways [18, 19]. Moreover, as Joyce and Loe [20] argue,
technologyingeneralisanimportantelementintheimagery,
expression,andperformanceofmodernageing.Theﬁrststep
of our approach, therefore, aims to reconstruct the history of
Alzheimer’s disease as a concept more or less distinct from
other diseases as well as “normal ageing,” and to investigate
how the existing boundaries between AD and ageing might
be redrawn by research into the biology of AD.
3. Technology, Alzheimer’s Disease, andAgeing
Several authors have reconstructed and analyzed the history
of Alzheimer’ disease [18, 19, 21]. They all share the observa-
tion that the label “Alzheimer’s disease” has been interpreted
and used in various ways since Kraepelin included it in
his nosology of psychiatric disease in 1910. Both scientiﬁc
andtechnologicaldevelopmentsanddevelopmentsinsociety
have inﬂuenced the way the disease was framed. The
evolving deﬁnitions, in turn, have signiﬁcantly determined
how society deals with elderly people displaying complaints
and signs that tend to be associated with dementia. Deﬁni-
tions of Alzheimer’s disease have coevolved with scientiﬁc
and technological as well as social developments. We will
highlight here a few excerpts of this history of interacting
technological and sociocultural developments, as a starting
point to explore how it might further evolve in the future.
The case Alzheimer himself described in 1907, which
wouldlaterbecomethebasisforKraepelin’sdeﬁnitionofAD,
was about a 51-year-old woman, Auguste D., who displayed
clinical features of what was then called “senile dementia.”
What initially distinguished her case from other cases of
senile dementia was her relatively young age. At autopsy,
however, Alzheimer observed another diﬀerence. The brain
tissue displayed not only the plaques often associated with
senile dementia. By using a newly developed silver staining
technique, Alzheimer also made visible speciﬁc neuroﬁbril-
lary tangles [22]. It soon became clear that these tangles
were present in many other cases of senile dementia as well,
including those of elderly patients. When Kraepelin deﬁned
“Alzheimer’s disease” a few years later, he therefore focused
on the clinical criterion of age; according to his deﬁnition,
AD was a form of pre-senile dementia. This immediately
engendered a discussion on the question whether the age
diﬀerence is suﬃcient to identify AD as a disease sui generis
(Alzheimer himself was among those who thought it was
not) and how both presenile and senile dementia relate to
ageing processes in general [18]. The identiﬁcation of AD as
distinctfromseniledementiaseemedtosuggestthat,whereas
the AD was clearly distinct from the normal ageing process,
seniledementiamightnotbesodiﬀerentfromnormalageing
after all [23].
Notwithstanding such debates, the age-based criterion
continued to be used for diagnosing AD till the 1970s. As
a result, the prevalence of the disease was not very high.
Only after the age criterion was dropped in the 1970s, the
number of people diagnosed with AD rose steeply [18].
This evolution from “presenile” and “senile dementia” to
“dementia (including the Alzheimer type)” can be under-
stood as the result of converging social and technological
developments that had been going on in the 1960s. On
the one hand, the position of elderly people in society had
changed. With the growing number of individuals living
well beyond 65, the “third age” started to be regarded as
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and if it was accompanied by marginalization and stigma,
this was due to social processes that should be changed. The
concept of “ageism” was coined in 1968 by gerontologist
Robert Butler to denounce all attempts to stereotype and
discriminate people just because they are old. From this
perspective, labeling elderly people as “senile” often was an
easy way not to take them seriously. It became politically
relevant to distinguish the broad, pejorative use of the term
senility from a careful biomedical diagnosis of dementia.
Such a diagnosis would at the same time help to protect the
golden shine of the third age against the gloomy shadow of
deterioration during the fourth age.
On the other hand, several developments in science and
technology intensiﬁed the search for a correlation between
the clinical symptoms of senility and pathological signs in
the brain [24]. The invention of novel counting methods
for the number of plaques and tangles in brain tissue, and
the emergence of electron microscopy, enabled novel takes
on the pathology related to AD and senile dementia. The
counting methods were thought to show that the density of
plaques relates to the severity of the clinical phenomena and
thus to make a case for a clear biological substrate for these
symptoms. Electron microscopic investigations of plaques
and tangles revealed that these had diﬀerent morphological
features. The plaques were identiﬁed in 1964 as consisting of
amyloid; the substance of the tangles would remain obscure
for some more time. The ﬁndings raised all kinds of novel
hypotheses with regard to the biological process underlying
theformationofplaquesandtanglesandtheirroleincausing
the clinical symptoms. Although the causal process itself
was not clear at all, the idea gained ground that dementia
and Alzheimer’s disease were essentially biological processes
and should be diagnosed and treated on that level [23].
As a result, the relative importance of clinical symptoms
and biological signs was reversed. The presence of brain
pathology became a prerequisite for diagnosing dementia in
general (including Alzheimer’s) [18].
Another signiﬁcant shift in the framing of Alzheimer’s
disease and ageing occurred in the 1970s and 1980s, when
neurotransmitters became an important focus of interest,
resulting in a strong focus on memory complaints. The
interest in neurotransmitters was due to developments in
therapeutic technology, which started with the observa-
tion that drugs blocking cholinergic activity in the brain
(prescribed to women in child birth) produce dementia
like memory disruptions. This was further developed into
the hypothesis that a lack of acetylcholine in the brain
led to neuronal death and subsequently to problems with
short term memory—the so-called “cholinergic hypothesis.”
This hypothesis led to several attempts to develop drugs
counteringthischolinergicdeﬁcit,resultingincholinesterase
inhibitors like tacrine. The eﬀects of these drugs were
limited, because they only slow down the degradation of
acetylcholine. When a substantial number of neurons have
died, the eﬀect of the drugs will decrease. Accordingly,
cholinesterase inhibitors can only be eﬀective in the early
stages of dementia.
What is striking in this episode from the history of
Alzheimer’s disease is that the complex phenomenology of
the disease was narrowed down to memory loss. Whereas the
deﬁnition of AD from the start had included a broad set of
symptoms,includingothercognitiveproblemsandpersonal-
ity problems, scientiﬁc and clinical attention now focused on
the loss of memory functions. Since deteriorating memory
is associated with ageing anyway, this narrow focus invited a
reconnection of AD and ageing. This connection is still visi-
ble today, in the often heard half cunning, half anxious com-
ment that “this shows I’m oﬀ on the Alzheimer track” when
a (in all likelihood minor) slip of memory has occurred. The
promises of drugs slowing down the process of memory loss
thus lead to an increased social anxiety about forgetfulness,
and a concurrent neglect of the other symptoms earlier is
thought to be correlated with AD and dementia.
The most recent episode highlighted in the history of AD
is the ﬂurry of genetic and subsequent molecular research
that started in the 1990s. With the invention of transgenic
mouse models and the rise of genetic research in humans,
the hunt was open for “the” gene causing AD. As with most
other diseases, results were more modest than hoped for.
To date, four genes have been identiﬁed that are related to
AD. Three of them (called APP, presenilin-1, and presenilin-
2) are linked to cases of AD beginning at an early age, and
they are usually transmitted in an autosomal dominant way.
These monogenetic variants of AD account for less than 1%
of all AD cases. A fourth gene (APOE) is associated with an
increased risk of AD in the general population (usually also
associated with early onset of the disease) and is thus one
cause among others in a multifactorial variant of AD [25].
Here, as before, the novel technologies engendered a shift
in the conceptualization of AD, now producing a distinction
betweengenetic(orfamilial)andsporadicAD,whichseemed
to be associated with, but not identical to, a distinction
between early and late onset AD. The identiﬁcation of
speciﬁc genetic risk groups has driven attempts to actively
screen individuals from such families with oﬀers of genetic
testing; however, most countries do not oﬀer population
screening for the common late-onset form of AD [26].
Even though the genetic variants of AD do not seem to
be veryprevalent,molecularresearchinto the functionof the
APP gene (and later also into the presenilin genes) led to an
inﬂuential hypothesis about the causal pathway underlying
AD: the amyloid cascade. The idea that AD is a disease
with progressive stages had been around for decennia [23].
The amyloid cascade hypothesis gave it a clear pathological
foundation, by tracing the presence of amyloid plaques and
the subsequent neuronal death back to genetic alterations
causing excessive production of Aβ42 protein [27, 28]. The
hypothesis, although not without critics and having evolved
substantially since it was ﬁrst proposed in 1991, is quite
inﬂuential in current AD research. It has strongly reinforced
thinking of AD as a gradual process, in which biological
changes precede clinical manifestations. This helped to make
sense of the long standing ﬁnding that some individuals who
during life did not display any clinical symptoms, at autopsy
do show the plaques and tangles characteristic for AD. The
conceptualisation of “a-symptomatic AD” in turn stimulated
proposals to develop molecular tools for early diagnosis of
AD.International Journal of Alzheimer’s Disease 5
Despite the recent emphasis on the biological processes
of AD, several authors stressed the importance of clinical
manifestations as well. Petersen et al. (1999) showed that
there is a group of people experiencing cognitive decline,
who do not satisfy current diagnostic criteria for AD.
Analogous to the presupposition of a gradually developing
process on the molecular level, they proposed to use the
label of “Mild Cognitive Impairment” for this group and
suggested that it may be a transitional stage between normal
functioning and dementia in general or AD in particular
[29]. The value of this concept is currently highly debated,
as it is unclear how it might relate to biological processes
[30]. It is clear, however, that current thinking on AD
both on the molecular and the clinical level tends towards
conceptualising the disease in terms of a gradual process
withsignsandsymptomsthatbecomemoremanifestastime
progresses.
4. The Futureof AD andAging: Some Scenarios
Given these ongoing changes in the clinical practice and
understanding of AD, the question is how the envisioned
early diagnosis will aﬀect the social and cultural meaning of
the disease and of aging in general. To assess such broader
impacts,wedeveloped“possiblefutures”orscenariosserving
two goals. First, they invite reﬂection on the broad range
of impacts technological development in the ﬁeld of AD
diagnostics may have. In addition, they enable early and
public deliberation on the desirability of such impacts, as
wellasidentiﬁcationoftheconditionsforcreatingadesirable
future.Whensubjectedtodebate amongabroadsetofstake-
holders,suchscenarioscanhelptodemocratisetechnological
development and steer it in a socially and ethically desirable
direction, thus contributing to a responsible innovation
process.
The scenarios presented here share a general starting
point: they presuppose that attempts to develop biomed-
ical technologies for early detection of AD, in one form
or another, will not suddenly disappear. Their form and
societal impact will depend, however, on the actual path of
development and their success, as well as their embedding,
all of which are unknown right now. These uncertainties can
be reduced to some extent, however, by three observations
based on the history of AD and ageing presented above.
First, promises and expectations with regard to explaining
and curing AD, even when widely shared in the research
community, often do not materialize. Second, up to now, it
has been diﬃcult to explain AD in terms of a single, linear
causal pathway. And ﬁnally, opening up bodily processes that
were formerly invisible often produces a fragmentation of
what counts as “normal bodily functioning.”
Starting from these general observations and inspired by
the speciﬁc conceptual and historical developments sketched
in Section 2, we developed three scenarios. In the ﬁrst, we
explore what might happen if current attempts to identify
molecular biomarkers for AD are successful. The second
scenario, in contrast, outlines a future in which it proves to
be diﬃcult to associate AD unequivocally with underlying
biological processes. The third scenario depicts a future
(further away in time than the ﬁrst two) in which initial
failures to identify informative biomarkers lead to novel
technological developments.
4.1. Scenario 1: Forgetfulness as a Biological Problem. This
scenario starts from the assumption that the promise of
molecular research is indeed realized: (a set of) biomarkers
is/are identiﬁed that neatly distinguishes a speciﬁc group
of people from others, in terms of their chance to develop
clinically manifest AD. Not only a substantial part of those
patients diagnosed with AD score positive on the biomarker,
but also many of those with MCI. This greatly reinforces
the legitimacy of the MCI label, which until recently was
still contested as a pseudodisease. In due time, research
shows that those MCI patients scoring positive on the
biomarker test are signiﬁcantly more likely to develop full-
blown AD in the years to come. This motivates several
memory clinics to experimentally introduce the biomarker
test in their diagnostic workup. There is some professional
and societal debate, however, whether it is ethically sound
to oﬀer this test in the absence of a cure for AD. What
u s ei si tt ok n o wt h a ty o ua r eo ﬀ on a prospect of gradual
decline if nothing can be done about it? Some neurologists
argue that the test may oﬀer reassurance to those who
test negative. Psychiatrists and gerontologists point out that
although a cure is lacking, therapeutic options and diﬀerent
care arrangements are available. Knowing your biomarker
status may help to make informed decisions with regard
to the future. In The Netherlands, some voices claim that
a positive biomarker test might enable people to lay down
clear advanced directives at what stage they consider their
life to have become worthless. This might help to solve the
diﬃcult situation AD patients applying for legal euthanasia.
Currently, such requests are usually rejected, either because
the patient’s situation is not yet clearly hopeless, or because
his/her mental capacities have deteriorated to such an extent
that the request is not considered autonomous anymore.
Others respond, however, that this is exactly the reason
to abstain from biomarker testing. In the end, the novel
professional guidelines for AD diagnostics advise to perform
a biomarker test, but only when the patient is well informed
about the implications, and when post test counselling is
provided in case of a positive test result.
As memory problems become clearly linked with bio-
logical functioning, subjective experience of one’s cognitive
functioning is more and more distrusted. Physicians are
confronted with an increase of middle aged individuals
wondering whether their cognitive functioning is deterio-
rating. Such worries are reinforced by self-tests for regular
cognitive checkups available on the internet, aiming to
sell training programs which promise to improve cognitive
functioning. Some employers are quick to oﬀer cognitive
check-ups as a service to their employees, stating that testing
is not meant to demote anybody, but might help to adjust
the working environment to one’s evolving capabilities. In
general, however, there is a poor relation between the results
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denounce these tests and advise to rely on medical diagnosis
only.
In due time, the drugs with a modest eﬀect only on AD
patients are found to eﬀectively prevent memory complaints
in asymptomatic individuals who score positive on the
biomarker test. This reinforces the demand for testing. It also
leads to a medicalization of memory loss and an increase in
social norms for cognitive functioning. Those who can no
longer live up to these demands are even slightly blamed,
because they could have opted for biomarker testing and
drug treatment earlier. The government and employers start
campaigns promoting “healthy ageing,” in which forgetful-
ness is presented as one of those annoying phenomena from
the past. Ultimately, almost everyone above age ﬁfty, only
a few stubborn people excepted, starts using the biomarker
test as a regular checkup. The test now actually serves as the
new golden standard for diagnosing AD. Neuropsychological
tests for diagnosing AD consequently almost go out of
use.
Only after a substantial number of years, psychiatrists
observe that the ratio between patients with dementia and
those with other diseases in mental hospitals and nursing
h o m e sh a sc h a n g e d .T h eh u g en u m b e ro fA Dp a t i e n t sh a s
decreased because people seek help earlier and memory
complaints can be treated quite eﬀectively. The number of
patientsdisplayingbehaviouralandpersonalitydisordershas
increased,however,partlybecausethesephenomenaarenow
no longer associated with AD. The success of the biomarker
tests, moreover, has decreased the funding as well as the
attention for these other complaints, resulting in a nursing
home population that is diﬃcult to deal with. Physicians
and nurses willing to work at such institutions are scarce;
in particular the young ones shy away from a confrontation
with a part of humankind that so obviously does not satisfy
what one would expect humans to be.
4.2. Scenario 2: Biomarkers as an Add-On to the Diagnostic
Toolbox. Despite the amount of time, work, and money
spent on the identiﬁcation of biomarkers for AD, the high
expectations of AD research at the beginning of the 21st
century do not materialize. MRI techniques seem to be able
to single out some groups of patients highly likely to develop
full-blown AD, but this targets only a very small subset of
the whole AD population. Moreover, quite a few patients
are excluded from having a 7T MRI because they have a
pacemaker or other metal implants. Insurance companies
are not willing to pay for MRI scans with an apparently
low added value, thus in fact blocking the inclusion of this
technologyinthediagnosticworkup.Biomarkersidentiﬁable
in CSF do slightly better: a CSF test combining several
biomarkers does identify a large subset of MCI patients likely
to develop AD. However, whereas it predicts quite well the
onset of memory complaints, there is no clear correlation
with other symptoms of AD. At consensus meetings to
prepare novel professional guidelines for AD diagnostics,
there is huge controversy whether or not to include the
CSF test. Ultimately, most countries include the test in the
guidelines, but only in conjunction with other laboratory
and clinical tests aiming to identify the full spectrum of
potential AD symptoms.
With the increase of potential tests included in the di-
agnostic workup, however, the chances of test results con-
tradicting each other increase as well, complicating the
diagnostic process. Some medical professionals start talking
in terms of “proven” and “suspected” cases of AD—with
proven referring to the presence of amyloid that is made
visible in vivo for the ﬁrst time in those that test positive on
the CSF test. Others argue that it would be more precise to
distinguish“amyloiddepositdisease”(ADD)asdistinctfrom
AD and MCI. Pharmaceutical companies that have invested
a lot of money in research how to counteract the amyloid
cascadeorganizeclinicalsymposiafocusingatthenovelADD
phenomenon, but they cannot hide that the results of their
research eﬀorts are as yet very limited.
On a less grand scale, research into the role of lifestyle
andenvironmentalfactorsincausingADcontinues.Thelack
of clear categories and associated therapies does engender
a lot of confusion and anxiety among elderly. Patient or-
ganizations for AD start campaigns to promote regular
cognitive check-ups for elderly (using the slogan “Don’t
forget to check your memory!”) and make such cognitive
self tests available on their website. If the result is below
average, people are advised to see a physician and ask for AD
diagnostics including the CSF test. This medical orientation
is contested by some physicians, elderly, and family members
of AD patients, leading to a split in the patient organization.
The mission of the novel patient organization is to help
people live well with dementia. This organization supports
projects designing new forms of housing or implementing
new ways of working with elderly in organizations, in due
time claiming some successes in improving quality of life
for both patients and their social environment. Most elderly
experiencing cognitive or behavioural problems, however,
are disappointed if they do not test positive on the CSF
test but receive the label MCI or “suspected” AD instead.
They feel they are sentenced to a vague but deadly disease,
without any prospect of a future cure. Moreover, both their
informal caregivers and the biomedical professionals start
treating them as if they were completely helpless already. “It’s
really annoying,” a lady from the patient organization says.
“Most of my friends have given a key of their house to the
neighbours, in case they might forget their key. But if I stand
some time in front of my door to ﬁnd my key, my neighbour
c o m e so u ta n ds a y s :D i dy o uf o r g e ty o u rk e ya g a i n ?L e tm e
open the door for you!”
4.3. Scenario 3: The Normal Becomes Personal. Ongoing AD
biomarker research deﬁnitely produces a huge increase in
data on individual bodily functioning, but it is diﬃcult to
identify biomarkers that are suﬃciently informative about
chances of developing AD. One of the problems is that many
biomarkers characterise very small groups only. Moreover,
those biomarkers that do identify substantial groups at risk
of AD often lead to conﬂicting results, which makes them
diﬃcult to interpret. This lack of clear progress makes
funding organizations wary to ﬁnance more biomarker
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come to a halt. Developments in the technology platforms
enabling biomarker tests do continue, however.
An important step is made when blood serum proves
to be as reliable as source of biomarkers as CSF. In ad-
dition, lab-on-a-chip technology or even ingested sensors
that communicate measuring results to a computer system
become available, making it possible to regularly perform
biomarkertestsinawaythatishardlyburdensometothetest
subjects.Thismotivatessomeresearcherstostartmonitoring
a set of biomarkers in healthy individuals and MCI and AD
patients. When this ambitious and time-consuming study
is completed, huge variations within these groups (instead
of between them) come to the fore. Subsequent prospective
research, with a larger set of healthy individuals, points
out that what is normal for one may be quite abnormal
for another person. On the long term, however, deviations
from one’s personal pattern prove to be informative with
regard to a person’s chances to develop complaints related to
AD.
After many years, then, the procedure for diagnosing AD
is radically transformed. Instead of having a one-time set
of tests in the memory clinic, people are sent home with
a monitoring device. What is more, physicians and patient
organizations alike start urging middle-aged people to have
the personal pattern of their AD biomarkers established
before decline sets in, because only this will provide a good
reference point for later diagnosis. The roles and responsi-
bilities of clinicians and patients are radically redistributed,
with the latter ones taking an active part in diagnosis. Some
patients (or rather clients, since they are healthy individuals)
become quite good at interpreting their test results in view
of their own functioning, deciding for themselves which
deviations are signiﬁcant and which ones are not. When
changes are deemed signiﬁcant, a set of therapeutic options
is advised. Next to the prescription of drugs (which still have
alimitedeﬀectiveness),clientsareurgedtocontinueworking
and be productive as long as possible, exercise regularly, and
eat healthy.
In general, people become more aware of their own
ageing process. Since they are regularly confronted with
changes in bodily parameters, they become also more
keen on identifying changes in their physical, cognitive,
and behavioural performance. Clinicians have a hard time,
though, ﬁrst of all because the role and inﬂuence of medical
professionals is on the wane. Large groups of people self-
conﬁdentlyassertthattheyareverywellcapableofmanaging
theirownhealth.Commercialcompaniesarealltoohappyto
oﬀer assistance: the market for web-based health monitoring
tools, personal health advice, and healthy ageing coaches
is booming. But even if people do seek medical advice, it
is diﬃcult to oﬀer it in an evidence-based way. Deciding
whether, when, and how to intervene becomes much more
complex, since scientiﬁc research is hardly able to keep
up with the data produced by ubiquitous and permanent
monitoring. Although, as some reﬂexive clinicians note, this
m i g h tb em o r el i k ea ni l l u s i o nl o s tt h a nar e a lc h a n g e .
With the beneﬁt of hindsight, they state, past medical
interventions now can be seen for what they always were:
experiments lacking a sound scientiﬁc basis.
5.DeliberatingSocioculturalImpacts
As said above, scenarios like the three presented here can be
used to broaden the imagination as well as the deliberation
of those who are involved or may be involved in the future.
The scenarios also enable discussion of what is actually
problematic in the current situation: what are the problems
and needs surrounding AD and how might the attempt
to detect AD early aﬀect those problems and needs? Such
exercises can be organised with stakeholders in various ways
[31, 32]. Generally deﬁned, stakeholders are (groups of)
actors who are invested in a particular outcome of the
envisioned technological developments, that is, they have
somethingtogainortolosefromit[33,34].Thisisnodoubt
the case for patients (in particular future ones), clinicians
(physicians, nurses, and all kinds of paramedics) involved in
the diagnosis and care for AD patients, family members and
other informal care givers, the technology developers (scien-
tists, industry), clinical guideline developers, and insurance
companies. But as the scenarios imply, impacts may be
felt as well by the elderly in general, those caring for the
elderly, employers, policy makers, and in the Dutch case even
the committees assessing euthanasia cases. When inviting
stakeholdersforengagementactivities,choiceswillhavetobe
made; a careful balancing of the number of participants and
their respective backgrounds is necessary to ensure an even
handed deliberation process. What is feasible depends, of
course, on the design of the deliberation (discussed below).
In addition to the question which groups to include, the
question how to ﬁnd representatives of the groups to be
included deserves attention. After all, not all individuals may
be representative of the group they are supposed to speak
for. In the case of AD, in particular, the inclusion of patients
requires careful consideration. If it is feasible to ﬁnd patients
diagnosed with AD willing to participate, these will usually
be at an early stage of the disease. To make sure that the voice
of those familiar with later stages is also heard, inclusion of
family members, nurses, or patient organizations should be
considered.
Once stakeholders have been identiﬁed, the question is
how to elicit their responses [32]. One method for doing
this is to convene so-called “focus groups”: homogeneous
groups of a particular type of stakeholders. In this case,
several meetings with diﬀerent groups are held, to probe
the considerations of, say, patients and elderly, clinicians,
and informal care givers, respectively. Having separate
deliberations with these groups has several advantages. First,
it enables the inclusion of a larger number of representatives
of a speciﬁc group, thus possibly disclosing a variety of
viewpoints among this group. In addition, it will be easier
to discern to what extent speciﬁc considerations are widely
shared within a speciﬁc group of stakeholders. Finally, in this
setting,itwilloftenbeeasiertocreateanatmosphereoftrust,
stimulating participants to voice all their considerations
withoutworryaboutbeingoverwhelmedbyothers.Thismay
holdparticularlyforpatientsandcaregivers.Ingeneral,then,
focus groups enable the disclosure of a rich variety of con-
siderations and viewpoints. Moreover, they lend themselves
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as well as the good qualities of the present situation can
be explored, before responses to ongoing developments are
probed by presenting scenarios like the ones outlined above.
The ultimate goal of any focus group is to list the conditions
future developments should satisfy for a speciﬁc group of
stakeholders to accept these developments. The conditions
identiﬁed can be technological, social, organizational, ﬁnan-
cial, or cultural. As a result, who will be the addressees of the
focus group’s conclusion is an open question.
Another method for probing stakeholders’ responses,
which may be combined with the focus group method, is to
bring diﬀerent stakeholders together in a larger interactive
setting. Since diﬀerent groups of stakeholders may radically
diﬀer from, or even contradict, each other, it can be diﬃcult
to weigh or prioritize outcomes of separate focus groups.
Moreover, it is unclear who is in the best position to
perform this weighing. In addition, the moral legitimacy
of all stakeholders’ considerations can increase when these
are checked and judged to be legitimate by a larger set
of stakeholders. In an interactive, multistakeholder setting,
chances will increase that the ultimate conclusions not
just seek to further the interests of a speciﬁc group, but
are based on widely shared values. Interactive deliberation
enables the production of truly ethical judgments. Finally,
the opportunities for creative thinking on how to address
the legitimate concerns of speciﬁc stakeholders may increase,
thus contributing not only to a well-considered problem
analysis, but also to possible solutions or improvements. The
actual process of deliberating the diﬀerent scenarios will not
diﬀerverymuchfromtheoneusedinfocusgroups,although
in an interactive setting the person chairing the session
will have to be even more diligent in explicitly connecting
participants to further listening and a serious consideration
of all that is brought to the fore.
If feasible, then, having several focus groups ﬁrst before
bringing stakeholders together in an interactive workshop
might combine the best of both worlds. In addition, a
thorough exploration of stakeholders’ views on the present
situation of AD diagnostics (in a descriptive and an evalu-
ative way) will help to keep the discussion focused on what
needs to be done here and now, as well as to improve the
understanding of participants’ responses to the scenarios in
thesubsequentphase.Byexplicitlyreturningtothediagnosis
of the present after having deliberated the imagined futures,
these deliberations are most likely to result in conclusions as
to what needs to be done, by whom, here and now to ensure
responsible innovation.
6. Conclusion
In view of the current investments pursuing molecular tech-
nologies for early diagnosis of Alzheimer’s disease, as well
as the recent proposals for expanding diagnostic categories
in guidelines for diagnosing this disease, it is important to
evaluate the broader impacts these developments may have
(and to some extent already have) on society and culture.
We have argued that such an assessment might enhance
the democratic character of technology development and
lead to more robust technologies. We also indicated that,
to be eﬀective, such an assessment should take place at a
relatively early stage of technology development. This paper
outlines how one might proceed in three steps, focusing in
particular on impacts on the way society views and deals
with ageing. First, a conceptual analysis of the history of
AD and aging provides valuable insights in the broader
impact of AD diagnosis. Secondly, these insights can be used
to create imaginative, plausible scenarios about the future,
which might then, thirdly, be used as input for deliberation
among stakeholders via focus groups and broad interactive
workshops. Ultimately, such a process will help to identify
the conditions for responsible innovation of AD diagnostics,
by enabling innovators and societal stakeholders to become
mutually responsive to each other’s needs and values.
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